RTTNews | Jan 13, 2022 07:24AM EST

07:24 Thursday, January 13, 2022 (RTTNews.com) - AstraZeneca (AZN.L, AZN) and Amgen, Inc. (AMGN) announced Thursday the availability of Tezspire (tezepelumab-ekko) for shipment to wholesalers in the US.

Tezspire was approved by the U.S. Food and Drug Administration (FDA) on December 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine.

Read the original article on RTTNews ( https://www.rttnews.com/3254848/astrazeneca-amgen-announce-market-availability-of-tezspire-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved